Details of the Drug Reposition

General Information of This Drug (ID: DM7R145)

• Drug Name: Oteseconazole (DM7R145)
• Synonyms: Otesaconazole; 1340593-59-0; VT-1161; UNII-VHH774W97N; VHH774W97N; CHEMBL3311228; (R)-2-(2,4-Difluorophenyl)-1,1-Difluoro-3-(1h-Tetrazol-1-Yl)-1-(5-(4-(2,2,2-Trifluoroethoxy)phenyl)pyridin-2-Yl)propan-2-Ol; Oteseconazole [USAN]; Oteseconazole (USAN/INN); SCHEMBL17113021; BDBM50046187; WHO 10138; DB13055; SB17420; HY-17643; CS-0016914; D11785; Q27291837; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol; 2-Pyridineethanol, alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1H-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (alphaR)-
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Vulvovaginal Candidiasis	DISRCR6D	1F23.10	Approved	[1]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Onychomycosis	DISE4C4D	EE12.1	Phase 2	[2]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215888.
• [2] ClinicalTrials.gov (NCT02267356) A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail. U.S. National Institutes of Health.